A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients
suffering an acute myocardial infarction.
The investigators hypothesise that treatment with intracoronary abciximab, a potent anti
platelet agent, at the time of coronary stent insertion, will improve microvascular function.